Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled dose-finding study of AC-101 in moderate to severe active ulcerative colitis
CTR20262583Phase 2Active
- Sponsor
- Accro Bioscience
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hlx22 in autoimmune colitis, sponsored by Accro Bioscience. Started Sep 2026; status: active.
02
Drugs
hlx22
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20262583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262583.